The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis ; volume:17 ; number:1 ; day:7 ; month:5 ; year:2022 ; pages:1-14 ; date:12.2022
Orphanet journal of rare diseases ; 17, Heft 1 (7.5.2022), 1-14, 12.2022
- Urheber
-
Costa, Enrico
Girotti, Silvia
Pauro, Francesca
Leufkens, Hubert G. M.
Cipolli, Marco
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-022-02350-5
- URN
-
urn:nbn:de:101:1-2022071520223342255738
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:21 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Costa, Enrico
- Girotti, Silvia
- Pauro, Francesca
- Leufkens, Hubert G. M.
- Cipolli, Marco
- SpringerLink (Online service)
Ähnliche Objekte (12)
CF Fungal Disease in the Age of CFTR Modulators
CFTR modulators response of S737F and T465N CFTR variants on patient-derived rectal organoids
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
Lived experiences of individuals with cystic fibrosis on CFTR-modulators
A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis
The FDA Changed Everything
The novel CFTR haplotype E583G/F508del in CFTR-related disorder
Overview of the side-effects of FDA- and/or EMA-approved targeted therapies for the treatment of hematological malignancies
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women
Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for Pseudomonas aeruginosa survival
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
CF Fungal Disease in the Age of CFTR Modulators
CFTR modulators response of S737F and T465N CFTR variants on patient-derived rectal organoids
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
Lived experiences of individuals with cystic fibrosis on CFTR-modulators
A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis
The FDA Changed Everything
The novel CFTR haplotype E583G/F508del in CFTR-related disorder
Overview of the side-effects of FDA- and/or EMA-approved targeted therapies for the treatment of hematological malignancies
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women
Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for Pseudomonas aeruginosa survival
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
CF Fungal Disease in the Age of CFTR Modulators
CFTR modulators response of S737F and T465N CFTR variants on patient-derived rectal organoids
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
Lived experiences of individuals with cystic fibrosis on CFTR-modulators
A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis
The FDA Changed Everything
The novel CFTR haplotype E583G/F508del in CFTR-related disorder
Overview of the side-effects of FDA- and/or EMA-approved targeted therapies for the treatment of hematological malignancies
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women
Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for Pseudomonas aeruginosa survival